Vanucizumab ELISA Kit (DT073038)

Datasheet Compartir producto Copiar información

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	DT073038
Descripción	Vanucizumab ELISA Kit (DT073038) — Quantitative sandwich ELISA for Vanucizumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Tipo de muestra	Plasma, Serum
Sensibilidad	0.156 μg/ml
Rango	0.31-5 μg/mL
Número de acceso	P15692 & O15123
Aplicaciones	ELISA
Método de detección	Colorimetric
Tipo de ensayo	Quantitative
Recuperación	80-120%
Envío	2-8 ℃
Estabilidad y almacenamiento	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Especificaciones	Vanucizumab
Nombres alternativos	RG-7221, RG7221, RO5520985, 1448221-05-3
Fondo	Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.
Nota	For Research Use Only.